clinical trial · NCT07545811
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate CancerJANX014
brief summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
started
Apr 15, 2026
primary completion
May 1, 2028
completion
Mar 1, 2029
last updated
Apr 22, 2026
official title
A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol